Strong evidence suggests the major limitations of approved IFN therapies are poor pharmacokinetics (PK) and dose limiting systemic toxicities that prevent robust IFN signaling on relevant immune populations within the TME and tumor draining lymph nodes. This evidence concerns the gene IFNA1 and neoplasm.